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Summary Ketoconazole, an antifungal agent, inhibits in vitro C17-C20 lyase, an enzyme involved in
androgen biosynthesis. Since adrenal and ovarian androgens are the main precursors of oestrogens in
postmenopausal women, the endocrine and therapeutic effects of high dose ketoconazole (400mg three times
a day) were evaluated in 14 postmenopausal women with advanced breast cancer. Testosterone levels were
suppressed significantly (37%, P<0.025), as was dehydroepiandrosterone sulphate, and androstenedione levels
showed a similar but non-significant fall. Seventeen hydroxyprogesterone levels rose significantly, as would be
expected if C17-C20 lyase was inhibited. There was no suppression of cortisol or oestrone levels. There was a
small suppression of oestradiol concentrations, reflecting a decrease in its precursor, testosterone. Sex
hormone binding globulin levels rose, which may be due to a decrease in testosterone. All the changes are
compatible with C17-C20 lyase as a major site of action in vivo. No responses occurred in 12 patients treated
with ketoconazole alone, but in 2 patients who were progressing on aminoglutethimide, testosterone levels
were suppressed and in one patient a partial response occurred. Ketoconazole was poorly tolerated due to
gastrointestinal toxicity. This study shows that C17-C20 lyase is a potential target for hormone therapy, and
that sequential blockade of enzymes involved in oestrogen biosynthesis should be further evaluated.
Ketoconazole is an oral antifungal agent, which was
reported to produce gynaecomastia on high dosage regimens
(De Felice et al., 1981). This led to investigation of its effects
on testosterone production.
It has been shown to inhibit testicular (Lambert et al.,
1986), adrenal (Couch et al., 1987) and ovarian (Di Mattina
et al., 1988) steroid biosynthesis in vitro and testicular (Pont
et al., 1982a) and adrenal steroid (Pont et al., 1982b, 1984)
biosynthesis in vivo. Several enzymes are inhibited, but the
most sensitive is C17-C20 lyase (Figure 1).
Blockade of this enzyme would decrease both adrenal and
testicular androgen production and ketoconazole has there-
fore been used to treat prostate cancer (Pont, 1987). It has
been used either as a single agent or in combination with
LHRH agonists (Allen et al., 1983).
Although the endocrine and therapeutic effects are well
documented in men, there are no studies in women with
breast cancer. In postmenopausal women, the major sources
of oestrogens are adrenal and ovarian androgens (Judd et
al., 1982, 1974; Grodin et al., 1973). Aromatase inhibitors
that prevent this interconversion are effective therapeutically
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Figure 1 Sites of action of ketoconazole. Sites at which
ketoconazole can inhibit hormone synthesis are 17 hydroxylase
(170H), C17-C20 lyase (17-20 lyase) and 11,B hydroxylase
(1IOH). Aminoglutethimide inhibits aromatase (arom).
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in postmenopausal (Harris et al., 1983a) and occasionally
premenopausal breast cancer (Bezwoda et al., 1987; Wander
et al., 1986). The latter effect has been ascribed to direct
inhibition of intratumour production of oestrogens from
androgens (Miller et al., 1982; Bezwoda et al., 1987), which
may be a major local oestrogen source in postmenopausal
women (Mehta et al., 1987). In patients failing to respond to
aromatase inhibitor therapy with aminoglutethimide, rises in
adrogens have been reported (Santen et al., 1982).
Thus, sequential enzyme blockade to inhibit androgen
production as well as inhibition of aromatase may produce
greater oestrogen suppression and enhanced therapeutic
effects. To evaluate this possibility, we investigated the
endocrine and therapeutic effects of high dose ketoconazole
in postmenopausal women with advanced breast cancer.
Patients and methods
Fourteen patients were studied. They were all postmeno-
pausal and had progressive breast carcinoma confirmed
histologically or cytologically. The majority had advanced
primary local disease. Patients had stopped previous endo-
crine therapy, which was tamoxifen (n=7) or low dose
aminoglutethimide (6) (Harris et al., 1986), a month or more
previously. Two patients who were progressing on amino-
glutethimide 125mg twice daily, hydrocortisone 20mg twice
daily, had ketoconazole added to their therapy. The endo-
crine data for these patients was analysed separately from
the others. The patient characteristics are shown in Table I.
Response was assessed by UICC criteria (Hayward et al.,
1977).
Ketoconazole was given as 200mg three times daily (tds)
with food, and, if well tolerated, the dose was increased after
1 week to 400mg tds. Patients were seen weekly for assess-
ment of toxicity, liver function tests and dosage modification
if there were side effects.
Plasma samples were taken at each attendance for testo-
sterone (T), 17-hydroxyprogesterone (170HP), A4 andro-
stenedione (M4A), sex hormone binding globulin (SHBG),
oestrone (E), oestradiol (E2), dehydroepiandrosterone sul-
phate (DHAS) and cortisol levels. They were measured by
immunoassays which we have described in detail previously
(Harris et al., 1983b, c).
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Table I Patient pretreatment characteristics
Age (years)
LMP (years)
DFI (months)
Wt. (kg)
Medianm
66
20
0
65
Previous endocrine therapy (ET)
Previous chemotherapy
Previous radiotherapy
Response to previous ET
Response to subsequent ET
Meani (s.d.)
66 (+12)
15 (+9)
9 (+15)
61 (±12)
11
4
8
5/11
3/11
Sites of' lisease
Soft
tissue
i1 12
Two o0
Liver m'or0e site.S
1 6
Pre- and post-treatment samples were compared by a non-
parametric method, Wilcoxon ranked sums, and P<0.05
taken as significant.
Results
Endlocrine e/ects of ketoconaZole
Testosterone concentrations fell significantly by 37% over a
3 week period (Figure 2). Androstenedione showed a non-
significant fall at week 1 (Table II). Oestrone and oestradiol
both showed a fall at week 1, but only in the case
of oestradiol was this significant (Figure 2). DHAS fell by
week 3.
In contrast, 170HP levels rose significantly at week 1 and
remained elevated at week 3 (Figure 2). SHBG rose over the
3 week period (Figure 2).
No significant changes occurred in cortisol levels.
In the case of 2 patients already on therapy with AG,
addition of ketoconazole produced suppression of testoster-
one levels (0.6 to 0.2nM, and 1.3 to 0.3nM).
Clinical effects of ketoconazole
No responses were seen in the 12 patients treated with
ketoconazole alone. The drug, however, was poorly tolerated
and 7 patients stopped therapy within 1-3 weeks because of
severe nausea (5) or vomiting (2). One patient stopped
because of confusion that was reversed after changing ther-
apy. Five stopped because of progressive disease, although
the drug was well tolerated.
In one patient who had shown a partial response to
aminoglutethimide, addition of ketoconazole at the time of
tumour progression produced a further partial response in
soft tissue disease for 5 months.
The median survival from start of ketoconazole was 1 year
and 3 months, median survival from first relapse or presen-
tation with locally advanced disease was 3 years 6 months.
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Figure 2 Endocrine effects of ketoconazole.
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The changes detected in the hormone profiles in our patients
are compatible with the reported sites of action of ketocona-
zole, although most studies have been carried out with
testicular or adrenal tissue (Nagai et al., 1987; Loose, 1983;
Sikka, 1985; Kan, 1985; Kowal, 1983; Malozowski, 1985).
Blood levels achieved with ketoconazole are in the range 3
201imol (Craven et al., 1983; Brass et al., 1982) and may be
expected to inhibit the following enzymes: adrenal 17 hyd-
roxylase (Ki 0.04yM), 17,20 desmolase (Ki 0.01 PM), 1If
hydroxylase (Ki 0.01 PM) (Couch et al., 1987), ovarian 17
hydroxylase (ID50 5pM) (Di Mattina et al., 1988). Thus
inhibition of C17-C20 lyase would be expected to reduce T
and A4A levels. As a consequence of depletion of these
substrates for aromatase E, and E2 may fall. It has recently
been shown that suppression of ovarian androgens by
LHRH agonists can lead to a reduction in E2 in postmeno-
pausal women (Dowsett et al., 1988), and suppression of
adrenal androgens with hydrocortisone can produce suppres-
sion of El and E2 (Alexieva-Figusch et al., 1987; Harris et
al., 1984). However, in men treated with ketoconazole,
although T fell, E, did not (Santen et al., 1983). This may
reflect differences between men and women in substrates
available to aromatase.
The major precursor of A4, 170HP, rose significantly. It is
not clear whether this is ovarian or adrenal in origin, or
comes from both glands. The major adrenal androgen
metabolite DHAS showed a significant fall which is prob-
ably due to adrenal blockade of C17-C20 lyase.
Although l7ox hydroxylasc is inhibited in some studies
(Couch et al., 1987), in others there is no effect (Nagai et al.,
1987; Lambert et al., 1986). In our patients, 17x hydroxylase
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Table 11 Hormone concentrations on hetoconazole
Atncldrostetnecliotne (nAM)
Week
0 1 3
1.1 0.6 1.1
1.1
13
0.4
NS
10
1.2
NS
10
Oe.strione (pM)
Week
0 1 3
94 55
115 37
- NS
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does not appear to be inhibited, since 170HP levels rose, as
Santen found in males treated with ketoconazole (Santen et
al., 1983). Since 17a hydroxylase and C17-C20 lyase activity
reside in the same enzyme, this suggests that ketoconazole
interacts selectively at only one active site in C17-C20 lyase
(Nakajin & Hall, 1981). Since C17-C20 lyase has been
demonstrated in human breast tumours, a direct local effect
may occur (Abul-Hajj et al., 1980).
The fall in oestrogens could be due to an inhibitory effect
of ketoconazole on aromatase which has been reported for
human placental aromatase (Ayub & Stitch, 1986). However,
it was not inhibitory to human ovarian aromatase (Di
Mattina et al., 1988), although other imidazole compounds
are potent aromatase inhibitors (Schieweck et al., 1988). Any
effect on aromatase could be of additive value if combined
with other classes of aromatase inhibitor.
Cortisone levels did not change significantly, although 11
hydroxylase is inhibited in vitro (Couch et al., 1987) and in
vivo (Pont et al., 1984), and urine free cortisol falls in men
treated with ketoconazole (Santen et al., 1983). Thus,
although it has been suggested that nausea and vomiting due
to ketoconazole could be due to Addisonian crisis (White &
Kendall-Taylor, 1985), this was not the case in our study.
SHBG levels rose and this may be due to the reduction in
testosterone levels, since androgens suppress SHBG synthesis
(Anderson, 1974).
The poor tolerance to ketoconazole in this population
precluded further endocrine studies. In studies with prostate
cancer, there was a high discontinuation rate (Pont, 1987),
although not as high as in this study. Gastric acidity is
required for absorption (Van Tyle, 1984) and it may be that
achlorhydria in an elderly female population led to lower
absorption and higher gastrointestinal side effects. Although
abnormal liver function can occur, there were no significant
abnormalities in this study (McCance et al., 1987; Lake-
Bakkar et al., 1987).
No responses were seen to ketoconazole alone, although
the patients were not intrinsically resistant to hormone
therapy, since 5 had previously responded, and 3 responded
to subsequent hormone therapy. One case of male breast
cancer has been described, who responded to ketoconazole
(Feldman, 1986). It is likely that the poor tolerance in our
study precluded adequate therapeutic assessment.
However, since one aim of the study was to assess the
possible use of sequential enzyme blockade to lower intra-
tumour oestrogen levels, ketoconazole was added to the
therapy of 2 patients who had initially responded to AG and
then progressed on AG. In both cases, testosterone levels fell
by more than 50% and this could deplete tumours of a
substrate required for intratumour oestrogen biosynthesis.
One patient responded.
This study shows that inhibition of C17-C20 lyase can be
achieved in postmenopausal women and produce a signifi-
cant fall in androgens. Better tolerated inhibitors may
produce synergistic effects with aromatase inhibitors and
provide a rational target for drug development.
We would like to thank Dr M.B. Emanuel, Director of Clinical
Research, Janssen Pharmaceuticals Ltd., for supplying us with
ketoconazole.
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